Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients

Abstract

Younger patients with <i>EGFR</i>-mutant NSCLC who had high disease burden were more likely to develop BM. Vimentin served as a biomarker for predicting BM and poor prognostic factor in <i>EGFR-</i>mutant patients. EMT pathway may be considered as a therapeutic target in these high-risk populations.